Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2018
Here are the related meetings in 2021:
MEETING CHANGE TO VIRTUAL: Emerging Cell Therapies: Realizing the Vision of NextGen Cell Therapeutics (A5)
Emerging Cell Therapies: Realizing the Vision of NextGen Cell Therapeutics (EK15)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Emerging Cellular Therapies: T Cells and Beyond (B6)
Organizer(s) Carl H. June, Marcela V. Maus and Bruce R. Blazar
February 11—15, 2018
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Oct 11, 2017
Abstract Deadline: Nov 9, 2017
Scholarship Deadline: Oct 11, 2017
Discounted Registration Deadline: Dec 13, 2017
Sponsored by BioLegend, Inc., Editas Medicine, Gilead Sciences, Inc., Juno Therapeutics, Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc. and Takeda Pharmaceutical Company Limited. This activity was supported by an educational grant from Celgene Corporation.
Joint Meeting:
Lymphocytes and their Roles in Cancer (R1)
Summary of Meeting:
A new community of researchers is emerging that focuses on studying and developing cellular therapies against cancer and chronic infections. The field is advancing rapidly due to our deepening understanding of cell biology. New technologies permit efficient cell culture, gene transfer and genetic editing, enabling autologous and allogeneic cell therapy. With rapid development of CAR T cells, breakthrough FDA approval status, and fast-tracking clinical trials, competition is fierce in the biotechnology and pharmaceutical industries. Cell therapies with stem cells and T cells are in advanced clinical development that will enable widespread use for cancer and chronic infections such as HIV. Infusions of regulatory T cells (Tregs) have the potential to benefit patients with autoimmunity and transplantation. A goal of this conference is to bring together basic and translational scientists from these fields to identify current opportunities and challenges in cell therapies. Another goal is to bridge the fields of effector T cell and Treg cell therapies. The interdisciplinary features of this meeting should facilitate new collaborations and interactions between investigators who would not normally meet.
View Scholarships/Awards
A new community of researchers is emerging that focuses on studying and developing cellular therapies against cancer and chronic infections. The field is advancing rapidly due to our deepening understanding of cell biology. New technologies permit efficient cell culture, gene transfer and genetic editing, enabling autologous and allogeneic cell therapy. With rapid development of CAR T cells, breakthrough FDA approval status, and fast-tracking clinical trials, competition is fierce in the biotechnology and pharmaceutical industries. Cell therapies with stem cells and T cells are in advanced clinical development that will enable widespread use for cancer and chronic infections such as HIV. Infusions of regulatory T cells (Tregs) have the potential to benefit patients with autoimmunity and transplantation. A goal of this conference is to bring together basic and translational scientists from these fields to identify current opportunities and challenges in cell therapies. Another goal is to bridge the fields of effector T cell and Treg cell therapies. The interdisciplinary features of this meeting should facilitate new collaborations and interactions between investigators who would not normally meet.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, February 11 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 15 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 16 in order to fully experience the meeting.
SUNDAY, FEBRUARY 11
MONDAY, FEBRUARY 12
TUESDAY, FEBRUARY 13
WEDNESDAY, FEBRUARY 14
THURSDAY, FEBRUARY 15
FRIDAY, FEBRUARY 16
Conference Program Print | View meeting in 24 hr (international) time
The meeting will begin on Sunday, February 11 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, February 15 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, February 16 in order to fully experience the meeting.
SUNDAY, FEBRUARY 11
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
8:00—9:00 AM
Welcome and Keynote Address
*
Carl H. June,
University of Pennsylvania, USA
*
Bruce R. Blazar,
University of Minnesota, USA
*
Marcela V. Maus,
Harvard Medical School, USA
Ton N. Schumacher,
Netherlands Cancer Institute, Netherlands
T Cell Recognition in Human Cancer
T Cell Recognition in Human Cancer
8:00—9:00 AM
Welcome and Keynote Address
*
Iannis Aifantis,
New York University School of Medicine, USA
Alexander Y. Rudensky,
HHMI/Memorial Sloan Kettering Cancer Center, USA
Regulatory T Cells and their Functions in the Tumor Microenvironment
Regulatory T Cells and their Functions in the Tumor Microenvironment
9:00—11:30 AM
CAR/TCR Preclinical
*
Carl H. June,
University of Pennsylvania, USA
Philip D. Greenberg,
University of Washington, USA
Making TCR-Modified T Cells Effective for Leukemia and Solid Tumors
Making TCR-Modified T Cells Effective for Leukemia and Solid Tumors
Coffee Break
Crystal L. Mackall,
Stanford University, USA
What’s Next? Preclinical Studies Paving the Way for Future CAR T Cell Trials
What’s Next? Preclinical Studies Paving the Way for Future CAR T Cell Trials
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, University of Washington, USA
Strategies to Improve the Efficacy of CAR T Cells in Solid Tumors
Strategies to Improve the Efficacy of CAR T Cells in Solid Tumors
Reno Debets,
Erasmus MC Cancer Institute, Netherlands
Short Talk: T Cell Receptors Equipped with ICOS Enhance T Cell Persistence and Mediate Sustainable Anti-Tumor Responses upon Adoptive T Cell Therapy
Short Talk: T Cell Receptors Equipped with ICOS Enhance T Cell Persistence and Mediate Sustainable Anti-Tumor Responses upon Adoptive T Cell Therapy
James Scott-Browne,
La Jolla Institute, USA
Short Talk: Transcriptional Control of CAR-T Cell Function in Solid Tumors
Short Talk: Transcriptional Control of CAR-T Cell Function in Solid Tumors
9:00—11:15 AM
Understanding Lymphocytic Malignancy: Leukemia and Lymphoma
*
Adolfo Ferrando,
Columbia University, USA
Louis M. Staudt,
NCI, National Institutes of Health, USA
The MYD88-TLR9-B Cell Receptor Complex as a Target for Therapy in Aggressive Lymphomas
The MYD88-TLR9-B Cell Receptor Complex as a Target for Therapy in Aggressive Lymphomas
Coffee Break
Charles G. Mullighan,
St. Jude Children's Research Hospital, USA
The Role of CREBBP Mutations in Drug Resistance in Acute Lymphoblastic Leukemia
The Role of CREBBP Mutations in Drug Resistance in Acute Lymphoblastic Leukemia
Katia Georgopoulos,
Massachusetts General Hospital, USA
Super-Enhancer Circuits in B Cell Development and Transformation
Super-Enhancer Circuits in B Cell Development and Transformation
Anastasia N. Tikhonova,
New York University Medical School, USA
Short Talk: Single-Cell Dynamics of Bone Marrow Microenvironment
Short Talk: Single-Cell Dynamics of Bone Marrow Microenvironment
2:30—4:30 PM
Workshop 1: Perspectives from Industry
*
Charles Sentman,
Geisel School of Medicine at Dartmouth, USA
Amy Gilbert,
Cell Design Labs, USA
Development of a SynNotch Combinatorial “and” Gate CAR T for Solid Tumors
Development of a SynNotch Combinatorial “and” Gate CAR T for Solid Tumors
Ian R. Hardy,
TCR2 Therapeutics, USA
Improving CAR-T Cell Function with Small Molecule Treatment during Production
Improving CAR-T Cell Function with Small Molecule Treatment during Production
Kelan Hlavaty,
SQZ Biotech, USA
Engineering T Cells Using a Microfluidic Intracellular Delivery Method for Cell Therapy
Engineering T Cells Using a Microfluidic Intracellular Delivery Method for Cell Therapy
Robert J. Hofmeister,
TCR2 Therapeutics, USA
A Novel T Cell Therapy Engaging the Complete T Cell Receptor
A Novel T Cell Therapy Engaging the Complete T Cell Receptor
Lenka V. Hurton,
ZIOPHARM Oncology, USA
Rapid Production of T Cells Co-expressing CAR and Membrane-bound IL-15 Potentiates Antitumor Activity and Promotes in vivo Memory
Rapid Production of T Cells Co-expressing CAR and Membrane-bound IL-15 Potentiates Antitumor Activity and Promotes in vivo Memory
Sumiti Jain,
Sangamo Therapeutics, USA
Precise T Cell Engineering using Enhanced Zinc-finger Nucleases (ZFNs) for Highly Specific and Efficient Dual Knock-Out of Endogenous T-Cell Receptor and HLA-Class I with Site-Specific Insertion of a CD19-CAR: Implications for Allogeneic T Cell Therapy
Precise T Cell Engineering using Enhanced Zinc-finger Nucleases (ZFNs) for Highly Specific and Efficient Dual Knock-Out of Endogenous T-Cell Receptor and HLA-Class I with Site-Specific Insertion of a CD19-CAR: Implications for Allogeneic T Cell Therapy
Inez Johanna,
University Medical Center Utrecht, Netherlands
Towards the Next Generation CAR T Cells with TEGs: In vivo Efficacy – Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow
Towards the Next Generation CAR T Cells with TEGs: In vivo Efficacy – Toxicity Profile in Xenografts of Primary Human AML Disease and Healthy Bone Marrow
Levi Rupp,
Cell Design Labs, USA
THROTTLETM CARs: A Novel Platform for Enhanced Safety and Efficacy via Titratable Control of CAR-T Activity using an FDA-Approved Small Molecule
THROTTLETM CARs: A Novel Platform for Enhanced Safety and Efficacy via Titratable Control of CAR-T Activity using an FDA-Approved Small Molecule
2:30—4:30 PM
Workshop 1: Understanding and Targeting Lymphocytes in Cancer
*
Iannis Aifantis,
New York University School of Medicine, USA
Eirini Giannakopoulou,
Radiumhospitalet, Norway
T Cell Receptor-Mediated Targeting of Recurrent Neoantigens in Acute Myeloid Leukemia
T Cell Receptor-Mediated Targeting of Recurrent Neoantigens in Acute Myeloid Leukemia
Wenting Zheng,
St. Jude Children Research Hospital, USA
PI3K Orchestration of the in vivo Persistence of Chimeric Antigen Receptor-Modified T Cells
PI3K Orchestration of the in vivo Persistence of Chimeric Antigen Receptor-Modified T Cells
Elena Montauti,
Northwestern University, USA
USP22 Maintains Regulatory T Cells by Stabilizing Foxp3 Protein Level and Impairs Anti-Tumor Immune Response
USP22 Maintains Regulatory T Cells by Stabilizing Foxp3 Protein Level and Impairs Anti-Tumor Immune Response
Jeffrey Ward,
Washington University School of Medicine, USA
Remodeling of Myeloid as well as Lymphoid Compartments following Checkpoint Blockade Immunotherapy
Remodeling of Myeloid as well as Lymphoid Compartments following Checkpoint Blockade Immunotherapy
Soki Kashima,
Kyoto University, Japan
WT1-Specific Cytotoxic T Lymphocytes Regenerated from T Cell-Derived iPS Cells Exert Therapeutic Effect in Xenograft Model of Renal Cell Carcinoma
WT1-Specific Cytotoxic T Lymphocytes Regenerated from T Cell-Derived iPS Cells Exert Therapeutic Effect in Xenograft Model of Renal Cell Carcinoma
Chris Nicolai,
University of California, Berkeley, USA
Mechanisms of MHC-Deficient Tumor Clearance using STING Agonists
Mechanisms of MHC-Deficient Tumor Clearance using STING Agonists
Julie Rytlewski,
Bristol-Myers Squibb, USA
History of Prior Immunotherapy Changes Relationship between Tumor Mutations and TIL Repertoire
History of Prior Immunotherapy Changes Relationship between Tumor Mutations and TIL Repertoire
Angela Vasaturo,
INSERM UMRS 1138, France
Unraveling the Immune Contexture of Pre-Invasive Lesions of the Lung by Multispectral Imaging
Unraveling the Immune Contexture of Pre-Invasive Lesions of the Lung by Multispectral Imaging
5:00—7:00 PM
Synthetic Biology
*
Crystal L. Mackall,
Stanford University, USA
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Chemically Engineering T Cell Therapies
Chemically Engineering T Cell Therapies
Wendell A. Lim,
University of California, San Francisco, USA
Optimizing Synthetic Biology Tools for T Cell Therapies
Optimizing Synthetic Biology Tools for T Cell Therapies
Travis Young,
California Institute for Biomedical Research, USA
Controllable CAR-T Cell Therapy
Controllable CAR-T Cell Therapy
Patrick Ho,
University of California, Los Angeles, USA
Short Talk: COVERT T Cells: Engineering T Cells to Interrogate Intracellular Antigens
Short Talk: COVERT T Cells: Engineering T Cells to Interrogate Intracellular Antigens
5:00—7:00 PM
Therapeutic Targeting of Lymphocytic Malignancy
*
Charles G. Mullighan,
St. Jude Children's Research Hospital, USA
Adolfo Ferrando,
Columbia University, USA
Epigenetic Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Epigenetic Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Iannis Aifantis,
New York University School of Medicine, USA
Targeting Stress Responses in Acute Lymphocytic Leukemia
Targeting Stress Responses in Acute Lymphocytic Leukemia
Andrei Thomas-Tikhonenko,
Children's Hospital of Philadelphia and University of Pennsylvania, USA
Escape Hatches for Immunotherapies Targeting B-Cell Differentiation Antigens
Escape Hatches for Immunotherapies Targeting B-Cell Differentiation Antigens
Jacques G. M. Ghysdael,
Institut Curie, France
Short Talk: Triggering the Tcr Developmental Checkpoint Activates a Therapeutically Targetable Anti-Leukemic Pathway in T-Cell Acute Lymphoblastic Leukemia
Short Talk: Triggering the Tcr Developmental Checkpoint Activates a Therapeutically Targetable Anti-Leukemic Pathway in T-Cell Acute Lymphoblastic Leukemia
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 AM
Engineered T Cells for Viruses
*
Philip D. Greenberg,
University of Washington, USA
Catherine M. Bollard,
Children’s National Health System, USA
Developing HIV-Specific T Cell Therapies: Lessons from EBV
Developing HIV-Specific T Cell Therapies: Lessons from EBV
Paula M. Cannon,
University of Southern California, Keck School of Medicine, USA
Shutting the Door on HIV by Engineering Hematopoietic Stem Cells
Shutting the Door on HIV by Engineering Hematopoietic Stem Cells
Coffee Break
James L. Riley,
University of Pennsylvania, USA
Engineering T Cells to Functionally Cure HIV-1 Infection
Engineering T Cells to Functionally Cure HIV-1 Infection
Scott G. Kitchen,
University of California, Los Angeles AIDS Institute, USA
Engineering Antiviral CAR T Cell Immunity through Hematopoietic Stem/Progenitor Cells
Engineering Antiviral CAR T Cell Immunity through Hematopoietic Stem/Progenitor Cells
Alok Vishnu Joglekar,
California Institute of Technology, USA
Short Talk: Hematopoietic Stem/Progenitor Cells Engineered with T Cell Receptors for Immunotherapy for HIV Infection
Short Talk: Hematopoietic Stem/Progenitor Cells Engineered with T Cell Receptors for Immunotherapy for HIV Infection
8:00—11:00 AM
Cellular Therapies in Blood Malignancies and Beyond
*
Ugur Sahin,
BioNTech AG, Germany
Carl H. June,
University of Pennsylvania, USA
CAR T Cells and their Therapeutic Promise in the Treatment of Leukemia
CAR T Cells and their Therapeutic Promise in the Treatment of Leukemia
Crystal L. Mackall,
Stanford University, USA
CAR Vulnerabilities: Emerging Insights from Clinical Trials
CAR Vulnerabilities: Emerging Insights from Clinical Trials
Coffee Break
Chiara Bonini,
Ospedale San Raffaele, Italy
Gene Editing of Memory Stem T Cells for Cancer Immunotherapy
Gene Editing of Memory Stem T Cells for Cancer Immunotherapy
Justin Eyquem,
University of California, San Francisco, USA
Precision T Cell Engineering to Advance Adoptive T Cell Therapies
Precision T Cell Engineering to Advance Adoptive T Cell Therapies
Charlotte Mousset,
Radboudumc, Netherlands
Short Talk: Superior Multi-Functionality and Glycolytic Function of Tumor-Reactive CD8+ TSCM-Like T Cells by ex vivo Akt-Inhibition
Short Talk: Superior Multi-Functionality and Glycolytic Function of Tumor-Reactive CD8+ TSCM-Like T Cells by ex vivo Akt-Inhibition
5:00—7:00 PM
CAR/TCR in the Clinic for Cancer
*
Jeffrey S. Miller,
University of Minnesota, USA
Stephen J. Forman,
City of Hope, USA
CAR T Cells for Treatment of Central Nervous System (CNS) Malignancy
CAR T Cells for Treatment of Central Nervous System (CNS) Malignancy
Marcela V. Maus,
Harvard Medical School, USA
CAR T Cells Multiple Myeloma and Glioblastoma
CAR T Cells Multiple Myeloma and Glioblastoma
Saar I. Gill,
University of Pennsylvania, USA
CAR T Cells for Acute Myelogenous Leukemia
CAR T Cells for Acute Myelogenous Leukemia
Jenessa Barbara Smith,
Poseida Therapeutics, USA
Short Talk: PSMA-Specific CAR T-Stem Cell Memory Therapy Eliminates Solid Tumor in Prostate Cancer Model
Short Talk: PSMA-Specific CAR T-Stem Cell Memory Therapy Eliminates Solid Tumor in Prostate Cancer Model
5:00—7:00 PM
Lymphocytes as Elements of the Tumor Microenvironment
*
Katia Georgopoulos,
Massachusetts General Hospital, USA
David H. Raulet,
University of California, Berkeley, USA
Natural Killer Cell Activation and Inhibition: Potential for Cancer Therapy
Natural Killer Cell Activation and Inhibition: Potential for Cancer Therapy
Michael Khodadoust,
Stanford University, USA
T Cell Recognition of Lymphoma Immunoglobulin
T Cell Recognition of Lymphoma Immunoglobulin
Mikala Egeblad,
Cold Spring Harbor Laboratory, USA
Visualization of the Switch from Immune Control to Immune Escape
Visualization of the Switch from Immune Control to Immune Escape
Annelise Snyder,
University of Washington, USA
Short Talk: Anti-tumor Effects of Inflammatory Necroptosis Within the Tumor Microenvironment
Short Talk: Anti-tumor Effects of Inflammatory Necroptosis Within the Tumor Microenvironment
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:15 AM
Tregs as Cellular Therapeutics
*
James L. Riley,
University of Pennsylvania, USA
Bruce R. Blazar,
University of Minnesota, USA
Vimentin Restrains Regulatory T-cell Suppression of Graft-versus-Host Disease
Vimentin Restrains Regulatory T-cell Suppression of Graft-versus-Host Disease
Jeffrey A. Bluestone,
University of California, San Francisco, USA
Manipulating Tregs to Control Tolerance in Autoimmunity and Cancer
Manipulating Tregs to Control Tolerance in Autoimmunity and Cancer
Coffee Break
Megan K. Levings,
University of British Columbia, Canada
HLA-A2 Directed CAR Tregs
HLA-A2 Directed CAR Tregs
David Klatzmann,
Sorbonne University Medical School, France
IL-2 for Treg-Based Immunotherapies: In (and Out)
IL-2 for Treg-Based Immunotherapies: In (and Out)
Angela C. Boroughs,
Massachusetts General Hospital/Harvard University, USA
Short Talk: 4-1BB Co-Stimulation Inhibits CAR Treg Suppressive Function
Short Talk: 4-1BB Co-Stimulation Inhibits CAR Treg Suppressive Function
Elmar Jaeckel,
Hannover Medical School, Germany
Short Talk: Operational Tolerance in Allotransplantation by Use of Regulatory T Cells with a MHC-Specific Chimeric Antigen Receptor
Short Talk: Operational Tolerance in Allotransplantation by Use of Regulatory T Cells with a MHC-Specific Chimeric Antigen Receptor
8:00—11:00 AM
Emerging Technologies: Visualization and Dissection of the Tumor Microenvironment
*
Mikala Egeblad,
Cold Spring Harbor Laboratory, USA
Dana Pe'er,
Memorial Sloan Kettering Cancer Center, USA
A Single Cell Approach to Understanding the Tumor Microenvironment
A Single Cell Approach to Understanding the Tumor Microenvironment
Matthew F. Krummel,
University of California, San Francisco, USA
Imaging a World beyond Checkpoints: Innate Partners for Lymphocytes in Cancer
Imaging a World beyond Checkpoints: Innate Partners for Lymphocytes in Cancer
Coffee Break
Jerome Galon,
INSERM UMRS1138, Cordeliers Research Center, France
Immunoscore as a Stronger Predictor of Patient Survival in Colorectal Cancer
Immunoscore as a Stronger Predictor of Patient Survival in Colorectal Cancer
Michael Goldberg,
Dana-Farber Cancer Institute, USA
Enhancing Cancer Immunotherapy through Immuno-engineering
Enhancing Cancer Immunotherapy through Immuno-engineering
2:30—4:30 PM
Workshop 2: Cell Engineering
*
Martin Pule,
University College London, UK
Zinaida Good,
Stanford University, USA
Guiding T-Lymphocyte Differentiation in Cancer Immunotherapy Applications
Guiding T-Lymphocyte Differentiation in Cancer Immunotherapy Applications
Rachel C. Lynn,
Lyell Immunopharma, USA
Disrupting the Balance: Engineering AP1 to Overcome CAR T Cell Exhaustion
Disrupting the Balance: Engineering AP1 to Overcome CAR T Cell Exhaustion
Shannon K. Oda,
Fred Hutchinson Cancer Research Center, USA
Cheating Death: A Fas-4-1BB Immunomodulatory Fusion Protein Obviates a Death Signal to Enhance T Cell Function and Adoptive Therapy Targeting Leukemia and Solid Tumors
Cheating Death: A Fas-4-1BB Immunomodulatory Fusion Protein Obviates a Death Signal to Enhance T Cell Function and Adoptive Therapy Targeting Leukemia and Solid Tumors
William Lemieux,
University of Montréal, Canada
Efficient Transduction of Nk Cells Method Resulting in a Robust and Sustained Transgene Expression for Immunotherapy
Efficient Transduction of Nk Cells Method Resulting in a Robust and Sustained Transgene Expression for Immunotherapy
Masataka Suzuki,
Baylor College of Medicine, USA
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments Chimeric Antigen Receptor T-Cell against Metastatic Head and Neck Cancer
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments Chimeric Antigen Receptor T-Cell against Metastatic Head and Neck Cancer
Tori Yamamoto,
NCI, University of Pennsylvania, USA
Cell Intrinsic Fas Signaling Inhibition to Improve Therapeutic Efficacy of T Cells
Cell Intrinsic Fas Signaling Inhibition to Improve Therapeutic Efficacy of T Cells
Nicholas F. Kuhn,
Memorial Sloan Kettering Cancer Center, USA
Design of a Systemic Antitumor Response with CD40L-modified CAR T Cells
Design of a Systemic Antitumor Response with CD40L-modified CAR T Cells
Joy (Yushu) Xie,
Massachusetts Institute of Technology, USA
Engineering Single Domain Antibody-Based Chimeric Antigen Receptor T Cells for Treatment of Solid Tumors
Engineering Single Domain Antibody-Based Chimeric Antigen Receptor T Cells for Treatment of Solid Tumors
5:00—7:00 PM
Beyond T Cells: HSC, T Progenitor and IPSCs I
*
Juan Carlos Zúñiga-Pflücker,
Sunnybrook Research Institute, Canada
Martin Pule,
University College London, UK
New Designs in Synthetic T Cells
New Designs in Synthetic T Cells
Jeffrey S. Miller,
University of Minnesota, USA
Novel Ways to Activate and Target NK Cells to Treat Cancer
Novel Ways to Activate and Target NK Cells to Treat Cancer
Linda T. Vo,
University of California, San Francisco, USA
T Cell Engineering from Human Pluripotent Stem Cells
T Cell Engineering from Human Pluripotent Stem Cells
5:00—7:00 PM
Emerging Concepts in the Development of Tumor Vaccines
*
Dimitris Skokos,
Regeneron Pharmaceuticals, USA
Ugur Sahin,
BioNTech AG, Germany
Systemic RNA Delivery, Dendritic Cell Vaccines and Implications for Cancer Immunotherapy
Systemic RNA Delivery, Dendritic Cell Vaccines and Implications for Cancer Immunotherapy
Cornelis J. M. Melief,
Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Combination Immunotherapy of Cancers Caused by High-Risk HPV16
Combination Immunotherapy of Cancers Caused by High-Risk HPV16
Johanna Olweus,
University of Oslo, Norway
Selecting Immunogenic Targets for Cancer Immunotherapy
Selecting Immunogenic Targets for Cancer Immunotherapy
Samarth Hegde,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: Tumor Antigenicity Accelerates Early Pancreatic Adenocarcinoma Progression
Short Talk: Tumor Antigenicity Accelerates Early Pancreatic Adenocarcinoma Progression
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 AM
Beyond T Cells: HSC, T Progenitor and IPSCs II
*
Bruce R. Blazar,
University of Minnesota, USA
Juan Carlos Zúñiga-Pflücker,
Sunnybrook Research Institute, Canada
Generation of Human Progenitor T Cells from Stem Cells
Generation of Human Progenitor T Cells from Stem Cells
Sjoukje J.C. van der Stegen,
Memorial Sloan Kettering Cancer Center, USA
Development of CD8alphabeta+ CAR T Cells from Human Pluripotent Stem Cells
Development of CD8alphabeta+ CAR T Cells from Human Pluripotent Stem Cells
Coffee Break
Saar I. Gill,
University of Pennsylvania, USA
Chimeric Antigen Receptor Macrophages for the Treatment of Solid Tumors
Chimeric Antigen Receptor Macrophages for the Treatment of Solid Tumors
Katelyn Masiuk,
University of California, Los Angeles, USA
Short Talk: Hematopoietic Stem Cell Gene Therapy for IPEX Syndrome
Short Talk: Hematopoietic Stem Cell Gene Therapy for IPEX Syndrome
8:00—11:00 AM
Combinatorial Treatments and their Effects on Lymphocyte Function in Cancer
*
Ashley M. Laughney,
Memorial Sloan Kettering Cancer Center, USA
David G. DeNardo,
Washington University Medical School, USA
The Pancreatic Tumor Microenvironment; Modulator of Tumor Progression and Response to Therapy
The Pancreatic Tumor Microenvironment; Modulator of Tumor Progression and Response to Therapy
Dimitris Skokos,
Regeneron Pharmaceuticals, USA
T Cell Dysfunction and Combination Immunotherapy
T Cell Dysfunction and Combination Immunotherapy
Coffee Break
Michael A. Curran,
University of Texas MD Anderson Cancer Center, USA
Optimizing T Cell Frequency and Function via Checkpoint Antibody / Vaccine Combinations
Optimizing T Cell Frequency and Function via Checkpoint Antibody / Vaccine Combinations
Sjoerd H. van der Burg,
Leiden University Medical Center, Netherlands
Combination Treatments to Modulate the Microenvironment and Boost Tumor-Specific T Cells
Combination Treatments to Modulate the Microenvironment and Boost Tumor-Specific T Cells
Yuliya Pylayeva-Gupta,
University of North Carolina at Chapel Hill, USA
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma
Short Talk: IL-35+ B Cells Establish Immunosuppressive Network in Pancreatic Ductal Adenocarcinoma
5:00—6:45 PM
Intersection of Genetic Editing and Cellular Therapy
*
Marcela V. Maus,
Harvard Medical School, USA
Alex Marson,
University of California, San Francisco, USA
Reprogramming Human T Cell Circuitry
Reprogramming Human T Cell Circuitry
Andrew M. Scharenberg,
Casebia Therapeutics, USA
Engineering Regulatory T Cells for Inflammatory Disorders
Engineering Regulatory T Cells for Inflammatory Disorders
Carl H. June,
University of Pennsylvania, USA
Adoptive Transfer with Genetically Edited T Cells
Adoptive Transfer with Genetically Edited T Cells
5:00—6:45 PM
Future Directions for Next-Generation Sequencing: Genomics, Epigenetics and Immunogenomics
*
Iannis Aifantis,
New York University School of Medicine, USA
Ashley M. Laughney,
Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Cell Plasticity and Population Interactions Supporting Metastasis using Single Cell Genomics
Dissecting Tumor Cell Plasticity and Population Interactions Supporting Metastasis using Single Cell Genomics
Mickey Atwal,
Cold Spring Harbor Laboratory, USA
High-Throughput Profiling of T Cell Receptor Sequences in Cancer Immunotherapy
High-Throughput Profiling of T Cell Receptor Sequences in Cancer Immunotherapy
Rahul Satija,
New York Genome Center, USA
Integrated Analysis of Single Cell Data across Modalities, Technologies and Species
Integrated Analysis of Single Cell Data across Modalities, Technologies and Species
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
